Can Ethanol Ablation Achieve Durable Control of Neck Nodal Recurrences in Adults With Stage I Papillary Thyroid Cancer?

IF 3 Q2 ENDOCRINOLOGY & METABOLISM Journal of the Endocrine Society Pub Date : 2024-02-27 eCollection Date: 2024-03-12 DOI:10.1210/jendso/bvae037
Ian D Hay, Robert A Lee, Carl C Reading, J William Charboneau
{"title":"Can Ethanol Ablation Achieve Durable Control of Neck Nodal Recurrences in Adults With Stage I Papillary Thyroid Cancer?","authors":"Ian D Hay, Robert A Lee, Carl C Reading, J William Charboneau","doi":"10.1210/jendso/bvae037","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Results of ethanol ablation (EA) for controlling neck nodal metastases (NNM) in adult patients with papillary thyroid carcinoma (APTC) beyond 6 months have rarely been reported. We now describe outcome results in controlling 71 NNM in 40 node-positive stage I APTC patients followed for 66 to 269 months.</p><p><strong>Methods: </strong>All 40 patients were managed with bilateral thyroidectomy and radioiodine therapy and followed with neck ultrasound (US) for >48 months after EA. Cumulative radioiodine doses ranged from 30 to 550 mCi; pre-EA 27 patients (67%) had 36 additional neck surgeries. Cytologic diagnosis of PTC in 71 NNM selected for EA was confirmed by US-guided biopsy. EA technique and follow-up protocol were as previously described.</p><p><strong>Results: </strong>The 40 patients had 1 to 4 NNM; 67/71 NNM (94%) received 2 to 4 ethanol injections (total median volume 0.8 cc). All ablated 71 NNM shrank (mean volume reduction of 93%); nodal hypervascularity was eliminated. Thirty-eight NNM (54%) with initial volumes of 12-1404 mm<sup>3</sup> (median 164) disappeared on neck sonography. Thirty-three hypovascular foci from ablated NNM (pre-EA volume range 31-636 mm<sup>3</sup>; median 147) were still identifiable with volume reductions of 45% to 97% observed (median 81%). There were no complications and no postprocedure hoarseness. Final results were considered to be ideal or near ideal in 55% and satisfactory in 45%. There was no evidence of tumor regrowth after EA.</p><p><strong>Conclusion: </strong>Our results demonstrate that for patients with American Joint Committee on Cancer stage I APTC, who do not wish further surgery or radioiodine, and are uncomfortable with active surveillance, EA can achieve durable control of recurrent NNM.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae037"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949354/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Endocrine Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jendso/bvae037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Results of ethanol ablation (EA) for controlling neck nodal metastases (NNM) in adult patients with papillary thyroid carcinoma (APTC) beyond 6 months have rarely been reported. We now describe outcome results in controlling 71 NNM in 40 node-positive stage I APTC patients followed for 66 to 269 months.

Methods: All 40 patients were managed with bilateral thyroidectomy and radioiodine therapy and followed with neck ultrasound (US) for >48 months after EA. Cumulative radioiodine doses ranged from 30 to 550 mCi; pre-EA 27 patients (67%) had 36 additional neck surgeries. Cytologic diagnosis of PTC in 71 NNM selected for EA was confirmed by US-guided biopsy. EA technique and follow-up protocol were as previously described.

Results: The 40 patients had 1 to 4 NNM; 67/71 NNM (94%) received 2 to 4 ethanol injections (total median volume 0.8 cc). All ablated 71 NNM shrank (mean volume reduction of 93%); nodal hypervascularity was eliminated. Thirty-eight NNM (54%) with initial volumes of 12-1404 mm3 (median 164) disappeared on neck sonography. Thirty-three hypovascular foci from ablated NNM (pre-EA volume range 31-636 mm3; median 147) were still identifiable with volume reductions of 45% to 97% observed (median 81%). There were no complications and no postprocedure hoarseness. Final results were considered to be ideal or near ideal in 55% and satisfactory in 45%. There was no evidence of tumor regrowth after EA.

Conclusion: Our results demonstrate that for patients with American Joint Committee on Cancer stage I APTC, who do not wish further surgery or radioiodine, and are uncomfortable with active surveillance, EA can achieve durable control of recurrent NNM.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乙醇消融能否持久控制甲状腺乳头状癌 I 期成人患者的颈部结节复发?
目的:乙醇消融术(EA)控制成年甲状腺乳头状癌(APTC)患者颈部结节转移(NNM)超过6个月的结果鲜有报道。现在,我们介绍了对 40 例结节阳性 I 期 APTC 患者随访 66 至 269 个月后控制 71 个 NNM 的结果:方法:所有 40 例患者均接受了双侧甲状腺切除术和放射性碘治疗,并在 EA 后接受颈部超声(US)随访超过 48 个月。累计放射性碘剂量从 30 到 550 mCi 不等;EA 前有 27 名患者(67%)接受了 36 次额外的颈部手术。通过 US 引导下的活组织切片检查,对 71 名入选 EA 的 NNM 患者进行了 PTC 细胞学诊断。EA技术和随访方案如前所述:40名患者中有1至4个NNM;67/71个NNM(94%)接受了2至4次乙醇注射(总注射量中位数为0.8毫升)。所有被消融的 71 个 NNM 都缩小了(平均体积缩小了 93%);结节血管过多的情况被消除。最初体积为 12-1404 mm3(中位数为 164)的 38 个非结节性血管瘤(54%)在颈部声像图上消失了。消融 NNM 的 33 个低血管病灶(EA 前体积范围为 31-636 mm3;中位数为 147)仍可识别,观察到体积缩小了 45% 到 97%(中位数为 81%)。手术无并发症,术后无声音嘶哑。55%的患者认为最终结果理想或接近理想,45%的患者认为最终结果令人满意。EA术后没有肿瘤再生的迹象:我们的研究结果表明,对于美国癌症联合委员会 I 期 APTC 患者,如果不希望进一步手术或放射碘治疗,也不愿意接受积极监测,那么 EA 可以实现对复发性 NNM 的持久控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of the Endocrine Society
Journal of the Endocrine Society Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.50
自引率
0.00%
发文量
2039
审稿时长
9 weeks
期刊最新文献
A Stronger IMPACT on Career Development for Early- and Mid-career Faculty. Blood Pressure Decreases in Overweight Elderly Individuals on Vitamin D: A Randomized Trial. Aromatase Inhibitor Monotherapy to Augment Height in Boys: Does It Work and Is It Safe? Efficacy of Tocilizumab in Refractory Graves Orbitopathy From Real-World Clinical Practice: An Observational Study. Sexual Dimorphism in the Immunometabolic Role of Gpr183 in Mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1